CD163在常见肿瘤中的临床意义及研究进展

doi:10.3969/j.issn.1004-583X.2022.07.014

摘要/Abstract

摘要：

CD163属于清道夫受体家族,是人体血红蛋白-触珠蛋白清除剂的亲和力受体,也是M2型肿瘤相关巨噬细胞表面特异性标志物。CD163是一种双重免疫调节剂,能够刺激免疫反应,又可以促进肿瘤细胞的增殖、侵袭及转移,在机体中发挥着重要的作用。目前,多项研究发现CD163对乳腺癌、肺癌、胃癌、胰腺癌、结直肠癌、肝癌等肿瘤的发生发展有很大的影响,这也深受很多学者的关注。本文就CD163的结构功能及在常见肿瘤中的研究进展及临床意义展开综述。

关键词: CD163, 肿瘤, 乳腺癌, 肺癌, 胃癌, 胰腺癌, 结直肠癌, 肝癌

中图分类号:

R730.5

成红军, 潘志昂, 祝成楼, 马继春, 李伟东, 逯涛峰, 达明绪. CD163在常见肿瘤中的临床意义及研究进展[J]. 临床荟萃, 2022, 37(7): 653-657.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.07.014

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I7/653

参考文献 53

[1]	Goldstein JL, Ho YK, Basu SK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein,producing massive cholesterol deposition[J]. Proc Natl Acad Sci USA, 1979, 76(1) :333-337. doi: 10.1073/pnas.76.1.333 URL
[2]	Canton J, Neculai D, Grinstein S. Sergio Grinstein Scavenger receptors in homeostasis and immunity[J]. Nat Rev Immunol, 2013, 13(9):621-34. doi: 10.1038/nri3515 pmid: 23928573
[3]	Li R, Ma H, Jiang L, et al. The CD163 long-range scavenger receptor cysteine-rich repeat: expression, purification and X-ray crystallographic characterization[J]. Acta Crystallogr F Struct Biol Commun, 2018, 74(Pt 5):322-326. doi: 10.1107/S2053230X18005551 URL
[4]	Freeman M, Ashkenas J, Rees DJ, et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors[J]. Proc Natl Acad Sci U S A, 1990, 87(22):8810-8814. doi: 10.1073/pnas.87.22.8810 pmid: 1978939
[5]	Martínez VG, Moestrup SK, Holmskov U, et al. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis[J]. Pharmacol Rev, 2011, 63(4):967-1000. doi: 10.1124/pr.111.004523 pmid: 21880988
[6]	Martínez VG, Moestrup SK, Holmskov U, et al. Crystal structure of the third extracellular domain of CD5 reveals the fold of a group B scavenger cysteine-rich receptor domain[J]. J Biol Chem, 2007, 282(17):12669-12677. doi: 10.1074/jbc.M611699200 pmid: 17322294
[7]	郭浩越, 毛锐, 王冉,等. 不同表型肿瘤相关巨噬细胞在肿瘤进展中的作用[J]. 中国肿瘤临, 2018, 45(9):482-486.
[8]	Nielsen MJ, Madsen M, Møller HJ, et al. The macrophage scavenger receptor CD163: endocytic properties of cytoplasmic tail variants[J]. J Leukoc Biol, 2006, 79(4):837-845. doi: 10.1189/jlb.1005602 URL
[9]	尚艳楠, 薛江东, 马德慧. CD163分子的研究进展[J]. 中国动物保健, 2015, 17(4):68-70.
[10]	Akila P, Prashant V, Suma MN, et al. CD163 and its expanding functional repertoire[J]. Clin Chim Acta, 2012, 413(7-8):669-674. doi: 10.1016/j.cca.2012.01.028 pmid: 22309681
[11]	Moreno JA, Muñoz-García B, Martín-Ventura JL, et al. The CD163-expressin m acrophages recognize and internalize TW EAK: Potential consequences in atherosclerosis[J] Atherosclerosis, 2009, 207(1):103-110. doi: 10.1016/j.atherosclerosis.2009.04.033 pmid: 19473660
[12]	Tarin C, Carril M, Martin-Ventura JL, et al. Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI[J]. Sci Rep, 2015, 5:17135. doi: 10.1038/srep17135 pmid: 26616677
[13]	Karrasch T, Brunnler T, Hamer OW, et al. Soluble CD163 is increased in patients with acute pancreatitis independent of disease severity[J]. Exp Mol Pathol, 2015, 99(2):236-239. doi: 10.1016/j.yexmp.2015.07.006 pmid: 26209500
[14]	Rojo-Martinez G, Maymo-Masip E, Rodriguez MM, et al. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study[J]. PLoS One, 2014, 9(6):e101250.
[15]	Maniecki MB, Etzerodt A, Ulhoi BP, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells[J]. Int J Cancer, 2012, 131(10):2320-2331. doi: 10.1002/ijc.27506 pmid: 22362417
[16]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[17]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[18]	Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68-and CD163-positive tumor-associated macrophages in triple negative cancer of the breast[J]. Virchows Archiv, 2020, 477(6):767-775. doi: 10.1007/s00428-020-02855-z URL
[19]	Shabo I, Stal O, Olsson H, et al. Breast cancer expres-sion of CD163, a macrophage scavenger receptor, is related to earlydistant recurrence and reduced patient survival[J]. Int J Cancer, 2008, 123(4):780-786. doi: 10.1002/ijc.23527 pmid: 18506688
[20]	Yang M, Li Z, Ren M, et al. Stromal infiltration of tumor-associated macrophages conferring poor prognosis of patients with basal-like breast carcinoma[J]. J Cancer, 2018, 9(13):2308-2316. doi: 10.7150/jca.25155 pmid: 30026826
[21]	Yu YR, Hotten DF, Malakhau Y, et al. Flow cytometric analysis of myeloid cells in human blood, bronchoalveolar lavage, and lung tissues[J]. Am J Respir Cell Mol Biol, 2016, 54(1):13-24. doi: 10.1165/rcmb.2015-0146OC URL
[22]	Yuan A, Hsiao YJ, Chen HY, et al. Opposite effects of m1 and M2 macrophage subtypes on lung cancer progression[J]. Sci Rep, 2015, 5:14273. doi: 10.1038/srep14273 pmid: 26399191
[23]	Matsubara E, Komohara Y, Shinchi Y, et al. CD163‐positive cancer cells are a predictor of a worse clinical course in lung adenocarcinoma[J]. Pathol Int, 2021, 71(10):666-673. doi: 10.1111/pin.13144 pmid: 34231937
[24]	Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Communications, 2019, 39(1) :22. doi: 10.1186/s40880-019-0368-6 URL
[25]	Zhang X, Peng Y, Jin Z, et al. Integrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinoma[J]. Oncotarget, 2015, 6(32):32878-32889. doi: 10.18632/oncotarget.5419 pmid: 26460735
[26]	Zhang WJ, Zhou ZH, Guo M, et al. High infiltration of polarized CD163+ tumor-associated macrophages correlates with aberrant expressions of CSCs markers, and predicts prognosis in patients with recurrent gastric cancer[J]. J Cancer, 2017, 8(3):363-370. doi: 10.7150/jca.16730 URL
[27]	Huang X, Pan Y, Ma J, et al. Prognostic significance of the infiltration of CD163+ macrophages combined with CD66b+ neutrophils in gastric cancer[J]. Cancer Med, 2018, 7(5):1731-1741. doi: 10.1002/cam4.1420 URL
[28]	Cheng Z, Zhang D, Gong B, et al. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer[J]. Oncotarget, 2017, 8(50):87244-87262. doi: 10.18632/oncotarget.20244 pmid: 29152078
[29]	Park JY, Sung JY, Lee J, et al. Polarized CD163+ tumor-associated macro-phages are associated with increased angiogenesis and CXCL12 expression in gastric cancer[J]. Clin Res Hepatol Gastroenterol, 2016, 40(3):357-365. doi: 10.1016/j.clinre.2015.09.005 URL
[30]	肖洪斌, 张莹. YAP1 蛋白表达在胰腺癌肿瘤异质性及病理诊断中的应用[J]. 实用肿瘤杂志, 2020, 35(6):530-533.
[31]	McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes[J]. World J Gastroenterol, 2018, 24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846 URL
[32]	Pan Y, Lu F, Fei Q, et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer[J]. J Hematol Oncol, 2019, 12(1):124. doi: 10.1186/s13045-019-0822-6 URL
[33]	Hu H, Hang JJ, Han T, et al. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer[J]. Tumour Biol, 2016, 37(7):8657-8664. doi: 10.1007/s13277-015-4741-z URL
[34]	Lim CY, Chang JH, Lee WS, et al. CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures[J]. Gut and Liver, 2021, 16(4):645-659. doi: 10.5009/gnl210311 pmid: 34933280
[35]	Cai L, Michelakos T, Deshpande V, et al. Role of tumor-associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs)[J]. Clin Cancer Res, 2019, 25(8):2644-2655. doi: 10.1158/1078-0432.CCR-18-1401 pmid: 30670493
[36]	Rami I, Qing C, Margaret B, et al. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor[J]. BMC Cancer, 2021, 21(1):320. doi: 10.1186/s12885-021-08045-7 pmid: 33765961
[37]	蒋娜, 隋燕霞, 蒋依娜, 等, 散发性结直肠癌微卫星不稳定状态与临床病理特征及预后的关系[J]. 安微医科大学学报, 2019, 54(1):139-142.
[38]	Shabo I, Olsson H, Sun XF, et al. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time[J]. Int J Cancer, 2009, 125(8):1826-1831. doi: 10.1002/ijc.24506 pmid: 19582880
[39]	Chen W, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer, 2019, 18(1):64. doi: 10.1186/s12943-019-0976-4 pmid: 30927925
[40]	Xue T, Yan K, Cai Y, et al. Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer[J]. World J Surg Oncol, 2021, 19(1):186. doi: 10.1186/s12957-021-02299-y pmid: 34167561
[41]	Nagorsen D, Voigt S, Berg E, et al. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: Relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival[J]. Transl Med, 2007, 5(1):62.
[42]	Minami K, Hiwatashi K, Ueno S, et al. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma[J]. Exp Ther Med, 2018, 15(5):4465-4476. doi: 10.3892/etm.2018.5959 pmid: 29731831
[43]	Kong LQ, Zhu XD, Xu HX, et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma[J]. PLoS One, 2013, 8(3):e59771.
[44]	Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma[J]. Cancer Sci, 2010, 101(8):1913-1919. doi: 10.1111/j.1349-7006.2010.01614.x URL
[45]	Kanno H, Nishihara H, Wang L, et al. Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma[J]. Neuro Oncol, 2013, 15(7):853-864. doi: 10.1093/neuonc/not028 URL
[46]	Andersen MN, Abildgaard N, Maniecki MB, et al. Monocyte/macrophage-derived soluble CD163: A novel biomarker in multiple myeloma[J]. Eur J Haematol, 2014, 93(1): 41-47. doi: 10.1111/ejh.12296 pmid: 24612259
[47]	He KF, Zhang L, Huang CF, et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma[J]. Biomed Res Int, 2014:838632.
[48]	Kridel R, Xerri L, Gelas-Dore B, et al. The Prognostic impact of CD163-positive macrophages in follicular lymphoma:a study from the BC cancer agency and the lymphoma study association[J]. Clin Cancer Res, 2015, 21(15):3428-3435. doi: 10.1158/1078-0432.CCR-14-3253 URL
[49]	Vajavaara H, Ekeblad F, Holte H, et al. Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma[J]. Haematologica, 2021, 106(9):2502-2506. doi: 10.3324/haematol.2020.278182 pmid: 33764002
[50]	Wang C, Hong T, Wang Y, et al. Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients[J]. Cancer Immunology, Immunotherapy, 2021, 70(10): 2925-2935. doi: 10.1007/s00262-021-02885-9 URL
[51]	Andersen MN, Abildgaard N, Maniecki MB, et al. Monocyte/macrophage-derived soluble CD163: A novel biomarker in multiple myeloma[J]. Eur J Haematol, 2014, 93(1):41-47. doi: 10.1111/ejh.12296 pmid: 24612259
[52]	Sugimura K, Miyata H, Tanaka K, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer[J]. Surg Oncol, 2015, 111(6):752-759.
[53]	Yagi T, Baba Y, Okadome K, et al. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer[J]. Eur J Cancer, 2019, 111:38-49. doi: S0959-8049(19)30039-5 pmid: 30822683

CD163在常见肿瘤中的临床意义及研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 53

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈思晗, 熊虎, 税典雅, 高小瞻, 刘泽伟. 超微血管成像技术诊断乳腺肿瘤的meta分析[J]. 临床荟萃, 2024, 39(2): 108-114.
[2]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[3]	黄赛虎, 龙中洁, 董兴强, 孟祥营, 吴水燕, 柏振江. 血液肿瘤患儿合并脓毒血症的病原学特点及临床特征[J]. 临床荟萃, 2024, 39(1): 38-42.
[4]	吕畅, 周利明. TNF-α-308基因多态性与胃癌易感相关性的meta分析[J]. 临床荟萃, 2023, 38(9): 779-787.
[5]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[6]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[7]	李亚, 杜涛明, 邱世香, 陈超, 钟立明. 伴有抑郁症状肝癌患者脑功能连接研究[J]. 临床荟萃, 2023, 38(6): 532-536.
[8]	赵哲, 穆培娟, 张冬. 恩度联合顺铂胸腔灌注治疗肺癌合并恶性胸腔积液疗效的meta分析[J]. 临床荟萃, 2023, 38(5): 399-404.
[9]	王英南, 赵琦, 白海威, 武丹娜, 魏金梅, 李省江, 李锐凌, 张瑞星. 胃癌合并脑梗死的临床特点及危险因素分析[J]. 临床荟萃, 2023, 38(5): 417-422.
[10]	周腾腾, 李来有, 刘志敏, 左静. 隧道式和传统PICC穿刺法对导管相关血流感染影响的研究进展[J]. 临床荟萃, 2023, 38(5): 469-472.
[11]	陆知非, 王高卿, 高过. 肝门部胆管癌的非手术治疗进展[J]. 临床荟萃, 2023, 38(5): 473-476.
[12]	黎恒楠, 黄艳, 赵亚娟, 胡桂才. 血清CTRP5与持续非卧床腹膜透析患者左室舒张功能异常的相关性及其诊断价值[J]. 临床荟萃, 2023, 38(4): 324-329.
[13]	罗杰, 吴强, 李忠, 郑硕. 罕见肾上腺神经纤维瘤1例并文献复习[J]. 临床荟萃, 2023, 38(4): 359-363.
[14]	彭灵智, 祝成楼, 刘天祥. 超级增强子:肿瘤治疗的新靶点[J]. 临床荟萃, 2023, 38(3): 273-278.
[15]	祝成楼, 吴琼, 达明绪. 西格列汀治疗2型糖尿病的胰腺癌风险评估:来自随机对照试验的荟萃分析结果[J]. 临床荟萃, 2023, 38(12): 1061-1066.